MESO•globenewswire•
Mesoblast Announces Changes to Board of Directors' Leadership Roles
Summary
NEW YORK, Jan. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that as foreshadowed at the recent Annual General Meeting the Board will undertake a number of changes in line with the Company's evolution to a revenue-generating commercial company.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 1, 2026 by globenewswire